EGFR and non-small cell lung carcinoma: The recent approval of the administration of osimertinib after complete surgical resection of IB-IIIA stage NS-NSCLC presenting with an actionable mutation in EGFR (L858R mutation and exon 19 deletion) based on the results of the ADAURA trial calls for the evaluation of EGFR mutations in early-stage NSCLC [69].